Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
TARS plans to discuss the path forward in these new indications with the US Food and Drug Administration. TARS has also reported sales of $13.1M from the first full quarter of Xdemvy's launch as a treatment for Demodex blepharitis. Tarsus Pharmaceuticals ( NASDAQ: TARS ) is only about six months into the launch of its eyedrop Xdemvy (lotilaner) for Demodex blepharitis. I wrote about the name in December, rating it a buy based on some positive preliminary signs (bottles delivered to patients plus Q3'23 sales numbers) and the clinical catalysts ahead. This article takes a look at the outcome of those clinical catalysts and another quarter of sales numbers. The Ersa trial reads out Firstly, in December 2023, TARS announced positive topline data from the phase 2a Ersa study of lotilaner ophthalmic solution in 39 patients with meibomian gland disease (MGD). There isn't a comparison to placebo in this trial, although the application of lotilaner twice a day or three times a day can
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon [Yahoo! Finance]Yahoo! Finance
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonGlobeNewswire
- Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14% [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
TARS
Earnings
- 2/27/24 - Beat
TARS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TARS's page on the SEC website